新型冠状病毒

Drugmakers race to scale up vaccine capacity

In the aftermath of the September 11 terror attacks, President George W Bush guaranteed that the US would pay $5.6bn for the production of vaccines and other countermeasures against bioterrorism.

That funding model, which led to the development of novel smallpox and anthrax prophylactics, will soon be deployed in the fight against Covid-19, as organisations including the World Bank and the Bill & Melinda Gates Foundation rush to underwrite the enormous costs of vaccine efforts.

But with more than 80 coronavirus vaccine candidates being developed around the globe, billions of dollars will have to be spent on preparing manufacturing facilities for several candidates, including some that will never make it to market.

您已阅读10%(721字),剩余90%(6399字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×